UC-Irvine researchers have found that an inhibitor of the potassium channel Kv1.3, a known autoimmunity target, may represent a new class of therapeutic for treating obesity-related diseases. The team has licensed the inhibitor, ShK-186, to Kineta and thinks it could treat the indication via a trio of distinct mechanisms.